Fernando R. Noriega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fernando R. Noriega has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
David R. Maneval
<!--label omitted: 1-->Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201
1 shared publicationFang Ming Liao
<!--label omitted: 1-->Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201
1 shared publicationMyron M. Levine
<!--label omitted: 1-->Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201
1 shared publicationSamuel B. Formal
<!--label omitted: 1-->Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201
1 shared publicationShuxun Ren
<!--label omitted: 1-->Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201
1 shared publication
Latest Publications
- 1 February 1999
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 67 (2) , 782-788
Strategy for Cross-Protection amongShigella flexneriSerotypes
Based upon the lipopolysaccharide (LPS) structure and antigenicity ofShigellagroup B, a strategy for broad cross-protection against 14Shigella flexneriserotypes was designed. This strategy involves the use of twoS. flexneriserotypes (2a and 3a), which together bear the all of the major antigenic group factors of this group. The novel attenuated strains used in these studies wereS. flexneri2a strain CVD 1207 (ΔguaB-A ΔvirG Δset1 Δsen) andS. flexneri3a strain CVD 1211 (ΔguaB-A ΔvirG Δsen). Guinea pigs were immunized with an equal mixture of these strains and later challenged (Sereny test) with a wild-typeS. flexneriserotype 1a, 1b, 2b, 4b, 5b, Y, or 6 strain of demonstrated virulence in the same model. Guinea pigs that were immunized with these two vaccine strains produced serum and mucosal antibodies that cross-reacted with all theS. flexneriserotypes tested (except ofS. flexneriserotype 6) as assessed by enzyme-linked immunosorbent assay, immunoblotting, and slide agglutination. Furthermore, the combination vaccine conferred significant protection against challenge withS. flexneriserotypes 1b, 2b, 5b, and Y but not with serotypes 1a, 4b, or (as predicted) 6.
- 1 February 1999
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 67 (2) , 782-788
Strategy for Cross-Protection amongShigella flexneriSerotypes
Based upon the lipopolysaccharide (LPS) structure and antigenicity ofShigellagroup B, a strategy for broad cross-protection against 14Shigella flexneriserotypes was designed. This strategy involves the use of twoS. flexneriserotypes (2a and 3a), which together bear the all of the major antigenic group factors of this group. The novel attenuated strains used in these studies wereS. flexneri2a strain CVD 1207 (ΔguaB-A ΔvirG Δset1 Δsen) andS. flexneri3a strain CVD 1211 (ΔguaB-A ΔvirG Δsen). Guinea pigs were immunized with an equal mixture of these strains and later challenged (Sereny test) with a wild-typeS. flexneriserotype 1a, 1b, 2b, 4b, 5b, Y, or 6 strain of demonstrated virulence in the same model. Guinea pigs that were immunized with these two vaccine strains produced serum and mucosal antibodies that cross-reacted with all theS. flexneriserotypes tested (except ofS. flexneriserotype 6) as assessed by enzyme-linked immunosorbent assay, immunoblotting, and slide agglutination. Furthermore, the combination vaccine conferred significant protection against challenge withS. flexneriserotypes 1b, 2b, 5b, and Y but not with serotypes 1a, 4b, or (as predicted) 6.